Informatie:
Fout:
ID
34612
Beschrijving
Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab); ODM derived from: https://clinicaltrials.gov/show/NCT02101307
Link
https://clinicaltrials.gov/show/NCT02101307
Trefwoorden
Versies (1)
- 19-01-19 19-01-19 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
19 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rheumatoid Arthritis NCT02101307
Eligibility Rheumatoid Arthritis NCT02101307
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT02101307
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Age
Item
patients at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Rheumatoid arthritis disease activity, moderate | Rheumatoid Arthritis Severe
Item
patients with a diagnosis of moderate to severe ra according to the revised (1987) acr criteria
boolean
C2368567 (UMLS CUI [1])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
RoActemra | Actemra
Item
patient in whom the treating physician has made the decision to commence roactemra/actemra treatment (in accordance with the local label). this can include patients who have received roactemra/actemra treatment within 8 weeks prior to the enrolment visit
boolean
C3272237 (UMLS CUI [1])
C2740854 (UMLS CUI [2])
C2740854 (UMLS CUI [2])
Informed Consent
Item
patient has given informed consent
boolean
C0021430 (UMLS CUI [1])
RoActemra Previous | Actemra Previous
Item
patients who have received roactemra/actemra more than 8 weeks prior to the enrolment visit
boolean
C3272237 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C2740854 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0205156 (UMLS CUI [1,2])
C2740854 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
RoActemra Previous Clinical Trial | Actemra Previous Clinical Trial | RoActemra Previous Compassionate Use | Actemra Previous Compassionate Use
Item
patients who have previously received roactemra/actemra in a clinical trial or for compassionate use
boolean
C3272237 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C2740854 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C3272237 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C2718016 (UMLS CUI [3,3])
C2740854 (UMLS CUI [4,1])
C0205156 (UMLS CUI [4,2])
C2718016 (UMLS CUI [4,3])
C0205156 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C2740854 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C3272237 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C2718016 (UMLS CUI [3,3])
C2740854 (UMLS CUI [4,1])
C0205156 (UMLS CUI [4,2])
C2718016 (UMLS CUI [4,3])
Investigational New Drugs
Item
patients who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with roactemra/actemra
boolean
C0013230 (UMLS CUI [1])
Autoimmune Disease | Inflammatory joint disease | Exception Rheumatoid Arthritis
Item
patients with a history of autoimmune disease or of any joint inflammatory disease other than ra
boolean
C0004364 (UMLS CUI [1])
C0683381 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0003873 (UMLS CUI [3,2])
C0683381 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0003873 (UMLS CUI [3,2])